Announcement • Jun 04
Menicon Co., Ltd. to Report Q1, 2027 Results on Aug 07, 2026 Menicon Co., Ltd. announced that they will report Q1, 2027 results on Aug 07, 2026 Announcement • May 13
Menicon Co., Ltd., Annual General Meeting, Jun 26, 2026 Menicon Co., Ltd., Annual General Meeting, Jun 26, 2026. Announcement • May 09
Menicon Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026 Menicon Co., Ltd. announced that they will report fiscal year 2026 results on May 13, 2026 Announcement • Jun 19
Menicon Co., Ltd. (TSE:7780) announces an Equity Buyback for 2,300,000 shares, representing 3.02% for ¥2,400 million. Menicon Co., Ltd. (TSE:7780) announces a share repurchase program. Under the program, the company will repurchase 2,300,000 shares, representing 3.02% of its share capital, for ¥2,400 million. The purpose of program is to improve shareholder's return. The repurchases will be funded from company's own funds. The program will run until December 20, 2025. As of May 31, 2025, the company had 76,060,964 shares outstanding (excluding treasury shares) and 683,024 shares in treasury. Announcement • May 14
Menicon Co., Ltd., Annual General Meeting, Jun 26, 2025 Menicon Co., Ltd., Annual General Meeting, Jun 26, 2025. Announcement • Dec 26
Menicon Co., Ltd. Introduces CO2-Free Electricity "Gifu Seiryu Green Electricity" to Kakamigahara Plant and Seki Plant Located in Gifu Prefecture Menicon Co., Ltd. announced that it has introduced CO2-free electricity "Gifu Seiryu Green Electricity" to Kakamigahara Plant and Seki Plant located in Gifu Prefecture. It is expected that approximately 9,300 tons of CO emissions will be reduced per year by introducing this product and proactive actions can be promoted to "reduce the burden on the global environment" through the local production and consumption of electric power. Announcement • Dec 25
Menicon Co., Ltd. Announces CEO Changes Menicon Co., Ltd. announced that Hidenari Tanaka as CEO effective March 31, 2025, in order to achieve more transparent management through "separation of ownership and management" and that Menicon has accepted his resignation. To appoint Koji Kawaura, CEO, effective April 1, 2025. The resignation is in order to achieve more transparent management through "separation of ownership and management". Hidenari Tanaka will resign as of March 31, 2025, and will assume the position of Honorary Chairman without representation rights as of April 1, 2025. Announcement • Dec 24
Menicon Co., Ltd. Announces Executive Changes Menicon Co., Ltd. announces that Hidenari Tanaka, Chairman, Director and Representative Executive Officer of Menicon, submitted a notice of resignation from the position of Chairman, Director and Representative Executive Officer of Menicon, effective March 31, 2025 in order to achieve more transparent management through "separation of ownership and management". In response, Menicon's Board of Directors, at a meeting held today, accepted the notice of resignation and resolved to change the Representative Executive Officer structure (from the current two-person Representative Executive Officer structure to a one-person structure) and to appoint Koji Kawaura, President and COO, Representative Executive Officer, President effective April 1, 2025. Declared Dividend • Nov 16
Dividend of JP¥28.00 announced Shareholders will receive a dividend of JP¥28.00. Ex-date: 28th March 2025 Payment date: 27th June 2025 Dividend yield will be 289%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (40% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 15% per year over the past 9 years and payments have been stable during that time. EPS is expected to grow by 75% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Oct 02
Menicon Co., Ltd. (TSE:7780) acquired Oculus Visioncare (S) Pte Ltd., Oculus (M) Sdn. Bhd. and PT. Oculus Indonesia from Oculus Private Limited. Menicon Co., Ltd. (TSE:7780) acquired Oculus Visioncare (S) Pte Ltd., Oculus (M) Sdn. Bhd. and PT. Oculus Indonesia from Oculus Private Limited on September 30, 2024.
Menicon Co., Ltd. (TSE:7780) completed the acquisition of Oculus Visioncare (S) Pte Ltd., Oculus (M) Sdn. Bhd. and PT. Oculus Indonesia from Oculus Private Limited on September 30, 2024. Announcement • Sep 23
Menicon Co., Ltd.(TSE:7780) dropped from FTSE All-World Index (USD) Menicon Co., Ltd.(TSE:7780) dropped from FTSE All-World Index (USD) Reported Earnings • Aug 13
First quarter 2025 earnings released: EPS: JP¥23.18 (vs JP¥20.75 in 1Q 2024) First quarter 2025 results: EPS: JP¥23.18 (up from JP¥20.75 in 1Q 2024). Revenue: JP¥30.2b (up 6.0% from 1Q 2024). Net income: JP¥1.77b (up 12% from 1Q 2024). Profit margin: 5.9% (up from 5.5% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 36% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €6.60, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 78% over the past three years. New Risk • Jul 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.6% average weekly change). Profit margins are more than 30% lower than last year (3.9% net profit margin). Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. Independent Outside Director Katsuhiko Yanagawa was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 19
Full year 2024 earnings released: EPS: JP¥59.63 (vs JP¥97.24 in FY 2023) Full year 2024 results: EPS: JP¥59.63 (down from JP¥97.24 in FY 2023). Revenue: JP¥116.2b (up 5.4% from FY 2023). Net income: JP¥4.54b (down 39% from FY 2023). Profit margin: 3.9% (down from 6.7% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 33% per year, which means it is performing significantly worse than earnings. New Risk • Apr 11
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.7% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (4.4% net profit margin). Announcement • Apr 04
Menicon Co., Ltd. (TSE:7780) acquired Laboratoires Dencott. Menicon Co., Ltd. (TSE:7780) acquired Laboratoires Dencott on March 22, 2024.
Menicon Co., Ltd. (TSE:7780) completed the acquisition of Laboratoires Dencotton March 22, 2024. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥25.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 26 June 2024. Payout ratio is a comfortable 37% but the company is not cash flow positive. Trailing yield: 1.5%. Lower than top quartile of German dividend payers (5.0%). In line with average of industry peers (1.6%). Announcement • Mar 02
Menicon Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024 Menicon Co., Ltd. announced that they will report fiscal year 2024 results on May 14, 2024 Announcement • Feb 29
Menicon Co., Ltd. Announces CFO Changes, Effective from April 1, 2024 Menicon Co., Ltd. announced that the meeting of the board of directors has resolved to make changes of its Executive Officers, effective April 1, 2024, as follows. The company approved the appointment of Hideki Koga as CFO and resignation of Motonari Watanabe as CFO, effective from April 1, 2024. New Risk • Feb 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Profit margins are more than 30% lower than last year (4.4% net profit margin). New Risk • Feb 14
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.4% Last year net profit margin: 7.4% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 14
Third quarter 2024 earnings released: EPS: JP¥16.48 (vs JP¥34.20 in 3Q 2023) Third quarter 2024 results: EPS: JP¥16.48 (down from JP¥34.20 in 3Q 2023). Revenue: JP¥29.3b (up 3.3% from 3Q 2023). Net income: JP¥1.26b (down 52% from 3Q 2023). Profit margin: 4.3% (down from 9.2% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Announcement • Feb 13
Menicon Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 Menicon Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company now expects net sales of JPY 116,000 million, operating profit of JPY 10,500 million, profit attributable to owners of parent of JPY 6,000 million and basic earnings per share of JPY 78.85 against net sales of JPY 116,000 million, operating profit of JPY 12,300 million, profit attributable to owners of parent of JPY 7,600 million and basic earnings per share of JPY 99.89 as previously forecasted. Buy Or Sell Opportunity • Feb 10
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 18% to €13.10. The fair value is estimated to be €10.91, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 12%. For the next 3 years, revenue is forecast to grow by 4.3% per annum. Earnings are also forecast to grow by 8.4% per annum over the same time period. Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €15.20, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 37% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.64 per share. Announcement • Dec 02
Menicon Co., Ltd. Announces the Launch of "1MONTH Menicon MelsME" and "1MONTH MeniconMelsME Toric Menicon Co., Ltd. announced the launch of "1MONTH Menicon MelsME" and "1MONTH MeniconMelsME toric, monthly replacement contact lenses made of silicone hydrogel material, particularly focusing on moisturization and wearing comfort, as MELS Plan exclusive contact lenses, in Japan from December 1, 2023. "MelsME" began as an MELS Plan exclusive brand. Hearts (ripples) resonate with one another and spread while forming big and small waves - This package design concept expresses cordial wish for people to feel the MELS Plan closer. MELS Plan is a subscription system to provide contact lenses at a monthly flat rate. The service users can use contact lenses according to changes in visual acuity and lifestyle without worry. More than 20 years after its launch, the service is currently used and highly evaluated by 1.35 million users. The newly launched MELS Plan exclusive brand "MelsME" employed the word "MELS" for the first time in products to express wish for the users to feel the MELS Plan closer. Reported Earnings • Nov 15
Second quarter 2024 earnings released: EPS: JP¥22.93 (vs JP¥28.25 in 2Q 2023) Second quarter 2024 results: EPS: JP¥22.93 (down from JP¥28.25 in 2Q 2023). Revenue: JP¥29.7b (up 8.8% from 2Q 2023). Net income: JP¥1.74b (down 19% from 2Q 2023). Profit margin: 5.9% (down from 7.9% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 13
First quarter 2024 earnings released: EPS: JP¥20.75 (vs JP¥27.98 in 1Q 2023) First quarter 2024 results: EPS: JP¥20.75 (down from JP¥27.98 in 1Q 2023). Revenue: JP¥28.4b (up 6.0% from 1Q 2023). Net income: JP¥1.58b (down 26% from 1Q 2023). Profit margin: 5.5% (down from 7.9% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Reported Earnings • May 18
Full year 2023 earnings released: EPS: JP¥97.24 (vs JP¥85.71 in FY 2022) Full year 2023 results: EPS: JP¥97.24 (up from JP¥85.71 in FY 2022). Revenue: JP¥110.2b (up 10.0% from FY 2022). Net income: JP¥7.38b (up 14% from FY 2022). Profit margin: 6.7% (up from 6.5% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥20.00 per share at 0.7% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 26 June 2023. Payout ratio is a comfortable 19% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.7%). Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: JP¥34.20 (vs JP¥25.89 in 3Q 2022) Third quarter 2023 results: EPS: JP¥34.20 (up from JP¥25.89 in 3Q 2022). Revenue: JP¥28.3b (up 7.7% from 3Q 2022). Net income: JP¥2.60b (up 33% from 3Q 2022). Profit margin: 9.2% (up from 7.4% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Announcement • Feb 02
Multifocal Colored Contact Lens “2Week Menicon Rei Multifocal” Launch in Japan Menicon Co., Ltd. (head office: 3-21-19, Aoi, Naka-ku, Nagoya-shi President and CEO: Hidenari Tanaka) will launch 2WEEK Menicon Rei multifocal, a 2weeks replacement multifocal colored contact lens in Japan on February 1, 2023. 2WEEK Menicon Rei is a series of contact lenses with an ultra-fine flower dot design that naturally blends with eye colors. 2WEEK Menicon Rei for myopia was released in 2014 and 2WEEK Menicon Rei toric for astigmatism in 2015, both of which have been well received. With the expansion of the colored contact lens market in recent years, the age groups of users have broadened with increased needs to ‘continue using colored contact lenses even after a change in vision with aging.’ 2WEEK Menicon Rei multifocal adopts the ‘progressive design’ that realizes natural vision from near to distance. Like 2WEEK Menicon Rei, it features 2 colors of ‘Nudy Brown’ and ‘Mild Black,’ enabling users to enjoy eye fashion with their favorite color while supporting their visual performance. 2WEEK Menicon Rei is the first colored contact lens made in Japan, manufactured in a domestic facility. The newly released multifocal type is also available through the MELS PLAN service, which is easily accessible at fixed monthly payments. Menicon will continue to propose a new ‘vision’ through the provision of products and services that meet the lifestyles and needs of individual users. (1) Progressive design to realize natural vision from near to distance Designed with three different zones (Near vision zone, Intermediate zone, Distance vision zone) in a balanced manner, the lens provides natural vision from near to distance. Visual performance varies among individuals. (2) Ultra-fine flower dot design that naturally blends with eye color The lens bears a flower pattern on it. Actually, this flower design is the secret to a natural look when wearing the lens. Contoured in the shape of a flower petal, the fine-grain ‘flower dots’ blend in with the color of the iris to create a seamless look around the lens periphery. (3) Just the right outer diameter of the colored area that creates a soft, doe-eyed effect (4) Covering film to keep color pigments from directly contacting the eye A covering film firmly prevents pigments from directly contacting the eye. (5) Stain-resistant non-ionic material Made of a non-ionic material that is highly resistant to protein deposits, the lens can be used comfortably over a two-week period. Wearing sensation varies among individuals. Brand name 2WEEK Menicon Rei Quantity 6 pieces/box Water content 72% Contact lens material Group II classification Base curve (mm) 8.6 Diameter (mm) 14.5 Spherical diopter power (D) ± 0.00 to -6.00 (0.25D steps), -6.50 to -10.00 (0.50D steps) Add power (D) + 1.00. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 2 highly experienced directors. Director Tokiyasu Tsuchida was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 29
Menicon Co., Ltd. Announces Price Revision for Menicon 1Day Series Menicon Co., Ltd. announced that the prices for "Menicon 1DAY" series, as well as the monthly fee of the MELS PLAN, will be revised sequentially from November 1, 2022. Menicon has been working on efficiency and on streamlining the company, putting in maximum efforts owing to the impact of increased procurement costs. However, the situation requires more than just company corporate efforts, and it has become difficult to maintain current pricing. Accordingly, the company have decided to revise the prices of the "Menicon 1DAY" series and the monthly fee of the MELS PLAN. The company will continue to take measures to address the increasing costs and to make efforts to provide safe and high-quality products. Menicon 1DAY: Revised sequentially from November 1, 2022. "Menicon 1DAY series" for MELS PLAN: Both eyes (Monthly cost); Menicon 1DAY & 1DAY Menicon toric: Before revision: ¥4,840 (Tax exclusive: ¥4,400). After revision: ¥5,060 (Tax exclusive: ¥4,600). Both eyes (Monthly cost); 1DAY Menicon Multifocal: Before revision: ¥5,940 (Tax exclusive: ¥5,400). After revision: ¥6,160 (Tax exclusive: ¥5,600). One eye (Monthly cost); Menicon 1DAY & 1DAY Menicon toric: Before revision: ¥3,190 (Tax exclusive: ¥2,900). After revision: ¥3,300 (Tax exclusive: ¥3,000). One eye (Monthly cost); 1DAY Menicon Multifocal: Before revision: ¥3,960 (Tax exclusive: ¥3,600). After revision: ¥4,070 (Tax exclusive: ¥3,700). 1DAY Plus: 1DAY Menicon Multifocal: Before revision: ¥2,970 (Tax exclusive: ¥2,700). After revision: ¥3,080 (Tax exclusive: ¥2,800). Reported Earnings • Aug 14
First quarter 2023 earnings released: EPS: JP¥27.98 (vs JP¥22.36 in 1Q 2022) First quarter 2023 results: EPS: JP¥27.98 (up from JP¥22.36 in 1Q 2022). Revenue: JP¥26.8b (up 12% from 1Q 2022). Net income: JP¥2.12b (up 26% from 1Q 2022). Profit margin: 7.9% (up from 7.0% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 6.8%, compared to a 7.5% growth forecast for the industry in Germany. Valuation Update With 7 Day Price Move • Jun 25
Investor sentiment improved over the past week After last week's 16% share price gain to €22.40, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 23% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €17.35 per share. Reported Earnings • May 14
Full year 2022 earnings released: EPS: JP¥85.71 (vs JP¥78.83 in FY 2021) Full year 2022 results: EPS: JP¥85.71 (up from JP¥78.83 in FY 2021). Revenue: JP¥100.2b (up 16% from FY 2021). Net income: JP¥6.48b (up 8.9% from FY 2021). Profit margin: 6.5% (down from 6.9% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 6.4%, compared to a 7.1% growth forecast for the industry in Germany. Announcement • May 12
Menicon Co., Ltd. Proposes for the Fiscal Year Ended March 31, 2022, Payable on June 24, 2022 Menicon Co., Ltd. proposes dividend JPY 20.00 per share for the fiscal year ended March 31, 2022, payable on June 24, 2022. Record date is March 31, 2022. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 2 highly experienced directors. Director Tokiyasu Tsuchida was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 01
Menicon Co., Ltd. Announces the Launch of Miru 1day UpSide toric in Europe Menicon Co., Ltd. hereby announced the launch of "Miru 1day UpSide toric", a silicon-hydrogel daily disposable contact lens for users with astigmatism, in Europe from April 1, 2022. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥17.50 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 25 June 2022. Payout ratio is a comfortable 18% but the company is paying out more than the cash it is generating. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (1.1%). Announcement • Mar 03
Menicon Co., Ltd. Announces the Launch of Menicon BloomTM Menicon Co., Ltd. announced the launch of Menicon BloomTM, a holistic treatment plan for myopia control in seven additional markets worldwide together with a powerful and impressive marketing campaign titled "See Their Imagination Bloom". Myopia, also known as near- or short-sightedness, is a common refractive error and one of the major causes of vision impairment worldwide. It affects approximately 30% of the world's population and its prevalence has been forecast to affect about 50% of the world's population by 2050. The prevalence of myopia in young adolescents has been increasing in recent decades to about 30% in industrialized societies of the West and epidemic levels of over 90% in some parts of Far East Asia. Globally, it is recognized as a significant public health concern associated with increased ocular-related morbidity and considerable healthcare costs. Concerned with the growing incidence of myopia and its health consequences worldwide, Menicon Co., Ltd. has developed Menicon BloomTM, a comprehensive treatment plan for childhood myopia that features two contact lenses that are CE- approved specifically for myopia control: Menicon Bloom NightTM, a specially designed orthokeratology contact lens, and Menicon Bloom DayTM, an extended depth of focus soft daily disposable contact lens. Combined with specially formulated Menicon BloomTM lens care solutions, fitting software and an innovative Menicon BloomTM app, this holistic treatment plan helps slow down the progression of childhood myopia while providing all the tools for a successful myopia journey. Menicon BloomTM was first introduced in the Netherlands in 2019. With this additional release, Menicon will launch across the United Kingdom, France, Spain, Italy, Austria, Australia, and Singapore starting March 2022. The launch demonstrates the company's continued commitment to offering on-label, approved products specifically for myopia control management to patients and eye care practitioners worldwide. The launch is being enhanced with an exciting marketing campaign titled "See Their Imagination Bloom" to raise awareness of childhood myopia and its possible treatment options. With a rich and vibrant visual world of imagination, the campaign aims to make it reassuringly easy for parents and eye care professionals around the world to incorporate the Menicon BloomTM treatment plan into children's daily routines. Reported Earnings • Feb 16
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Third quarter 2022 results: EPS: JP¥25.89 (up from JP¥22.81 in 3Q 2021). Revenue: JP¥26.3b (up 20% from 3Q 2021). Net income: JP¥1.96b (up 14% from 3Q 2021). Profit margin: 7.4% (down from 7.9% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 5.6%. Over the next year, revenue is forecast to grow 7.0%, compared to a 12% growth forecast for the industry in Germany. Announcement • Feb 15
Menicon Co., Ltd. Provides Earning Guidance for the Fiscal Year Ending March 31, 2022 Menicon Co., Ltd. provided earning guidance for the fiscal year ending March 31, 2022. For the period, the company expects net sales of JPY 99,400 million, operating profit of JPY 9,600 million, ordinary profit of JPY 9,500 million, profit attributable to owners of parent JPY 6,000 million and basic earnings per share JPY 79.36. Board Change • Feb 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 2 highly experienced directors. Director Tokiyasu Tsuchida was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jan 12
Menicon Co., Ltd. Announces Daily Disposable Lens “1Day Menicon PremiO Multifocal” Launch in Japan Menicon Co., Ltd. announced that "1DAY Menicon PremiO multifocal" daily disposable multifocal contact lenses will be released on January 11, 2022. As people age, they tend to have difficulty in seeing nearby objects clearly. Also, using smartphones for long hours puts increased strain on the eyes. Accordingly, people in their forties and even their thirties have difficulties focusing on nearby objects. 1 In recent years, the market for multifocal contact lenses has grown every year. The 1DAY Menicon PremiO Series have been used by many people since its launch. They are the first domestically produced daily disposable contact lenses using silicone hydrogel material that achieves both high oxygen permeability and comfort while being worn, with SMART TOUCH that enables users to remove a lens from the container cleanly and easily without touching the lens surface. The 1DAY Menicon PremiO multifocal lens provides natural and comfortable vision at any distance with its smooth optical power distribution design for seeing near, medium, and faraway distances clearly with one lens. In the MELS PLAN with the flat-rate system, 1DAY Menicon PremiO multifocal lenses are available at the same monthly cost as myopia lenses and astigmatism lenses. Thus, contact lens users can readily use these high-quality multifocal lenses. Menicon proposes a new "vision" through the provision of products that meet the lifestyle and needs of each customer. Reported Earnings • Nov 14
Second quarter 2022 earnings released: EPS JP¥22.63 (vs JP¥23.97 in 2Q 2021) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: JP¥24.3b (up 12% from 2Q 2021). Net income: JP¥1.71b (down 5.4% from 2Q 2021). Profit margin: 7.0% (down from 8.3% in 2Q 2021). The decrease in margin was driven by higher expenses. Reported Earnings • Aug 13
First quarter 2022 earnings released: EPS JP¥44.72 (vs JP¥36.76 in 1Q 2021) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2022 results: Revenue: JP¥24.1b (up 22% from 1Q 2021). Net income: JP¥1.69b (up 22% from 1Q 2021). Profit margin: 7.0% (in line with 1Q 2021). Announcement • May 21
Menicon Co., Ltd. Launches Daily Disposable Circle Lens 1Day Menicon Rei in Japan Menicon Co., Ltd. released daily disposable circle lens, "1DAY Menicon Rei" at MELS PLAN member shops nationwide from May 21, 2021. "1DAY Menicon Rei's" three color variations make the eyes appear naturally larger with the gradation of three tones of colors overlapping each other. The lenses produce "radiant eyes" according to each color variation. These three colors are "Flare Beige" producing natural radiant eyes, "Illumi Brown" producing dynamic radiant eyes, and "Glow Ash" producing chic radiant eyes. Since users can freely choose any combination of these three colors using the flat-rate system of MELS PLAN, they can choose the color of their lens according to the feel, makeup, or outfit of the day. Users can decide the combination of colors on a box basis and receive them in MELS PLAN. Circle lens series "Rei" have been used as two-week disposable contact lenses since their release in 2014. Now, daily disposable type lenses are available, which enables customers to choose products according to their needs. Since users pay a fixed amount for the MELS PLAN every month, they do not have to worry about the cost, which may otherwise be high due to the daily usage of circle lenses. Also, when users change lenses due to certain issues, such as a stained lens, they can receive the next month's lenses early, and thus safely use new lenses to ensure good eye health. Minami Hamabe promotes three attractive characteristics according to the different aspects of three types of lenses. Lens color variations: Flare Beige, Illumi Brown and Glow Ash. Features: 3-tone gradation: The three colors overlap each other and produce natural large and radiant eyes. The UV cut function will protect eyes by reducing the effects of UV rays that cause eye disorders: UV-A waves: decreased by 50%, UV-B waves: decreased by 95% (when measured with a -3.00D lens). High moisture content material in 58% of the lens, makes it soft and helps users comfortably wear the lenses. The lenses enveloped by "MPC*2 polymer", a high molecular moisturizing ingredient that is mixed in the lens solution, keep their moisture all day long. Thus, users can comfortably wear the lenses. The colored part of the lens containing pigment does not directly come in contact with the eyes because of its sandwich structure. "1DAY Menicon Rei" will be released as a special product for the fixed amount system MELS PLAN at MELS PLAN member shops nationwide. Reported Earnings • May 16
Full year 2021 earnings released: EPS JP¥158 (vs JP¥112 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥86.2b (up 2.0% from FY 2020). Net income: JP¥5.95b (up 47% from FY 2020). Profit margin: 6.9% (up from 4.8% in FY 2020). Announcement • May 13
Menicon Co., Ltd. Announces Dividend for the Fiscal Year Ended March 31, 2021 Menicon Co., Ltd. at its board meeting held on May 13, 2021 passed a resolution regarding its year-end dividend of surplus for the fiscal year ending March 31, 2021. The company announced year-end dividend of JPY 35.00 per share compared to previous dividend guidance of JPY 30.00 per share. Announcement • Mar 04
Menicon Co., Ltd. to Report Fiscal Year 2021 Results on May 13, 2021 Menicon Co., Ltd. announced that they will report fiscal year 2021 results on May 13, 2021 Is New 90 Day High Low • Feb 16
New 90-day high: €59.33 The company is up 5.0% from its price of €56.55 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 28% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €23.08 per share. Reported Earnings • Feb 13
Third quarter 2021 earnings released: EPS JP¥45.62 (vs JP¥27.60 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥21.9b (up 6.7% from 3Q 2020). Net income: JP¥1.72b (up 71% from 3Q 2020). Profit margin: 7.9% (up from 4.9% in 3Q 2020). The increase in margin was driven by higher revenue. Analyst Estimate Surprise Post Earnings • Feb 13
Revenue beats expectations Revenue exceeded analyst estimates by 2.0%. Over the next year, revenue is forecast to grow 5.8%, compared to a 14% growth forecast for the Medical Equipment industry in Germany. Announcement • Feb 12
Menicon Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2021 Menicon Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2021. The company now expects net sales of JPY 85,899 million, operating profit of JPY 8,006 million, profit attributable to owners of parent of JPY 5,308 million and basic earnings per share of JPY 140.63 compared to previous forecast net sales of JPY 84,839 million, operating profit of JPY 6,838 million, profit attributable to owners of parent of JPY 4,256 million and basic earnings per share of JPY 112.78. Is New 90 Day High Low • Jan 07
New 90-day low: €48.54 The company is down 16% from its price of €57.65 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.58 per share. Is New 90 Day High Low • Dec 23
New 90-day low: €48.82 The company is down 16% from its price of €58.02 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.68 per share. 
